Lifecare ASA · OSL:LIFE

Lifecare ASA — FY2021 Earnings Presentation

17 slides from Lifecare ASA's earnings presentation, Apr 21, 2022

  1. Slide 1: Lifecare FY 2021

    Lifecare FY 2021 21 April 2022

  2. Slide 2: Contents

    Contents 1. Highlights 2021 2. Key financial figures 2021 3. Cash Flow 4. Outlook 5. Sencell market potential 6. Valuedriven future milestones 2

  3. Slide 3: Highlights 2021

    Highlights 2021 Regulatory approval for first-in-human pilot clinical trials In February 2021 the German Federal Institute for Drugs and Medical Devices (BfArM) approved the trial protocol for Lifecares first-in-human Sencell study. Restructuring the organization – controlling development operations

  4. Slide 4: 2021 Delivering on our strategy

    2021 Delivering on our strategy Lifecare (mother) Lifecare NanoBioSensors Lifecare Laboratory • Establishing wholly owned and • Included in the 2021 numbers from • Access to highly qualified controlled development 1 Jul. 2021. personnel departments by acquiring two • Strong development focus, • Offi

  5. Slide 5: Consolidated Key Financial Figures

    Consolidated Key Financial Figures Lifecare Consolidated Financial Statements Assets Liabilities Period 1-12 2021 2021 2020 Period 1-12 2021 2021 2020 Period 1-12 2021 2021 2020 OPERATING INCOME 1 599 088 5 390 651 LICENCES AND PATENTS 7 185 530 212 000 PAID UP EQUITY 39 193 659 32 511 268 GOODWILL

  6. Slide 6: Cash Flow and selected notes

    Cash Flow and selected notes Lifecare Group Selected notes: Period 1-12 2021 2021 2020 1. Operating income The Lifecare Group has operating income of 1,6 MNOK, whereof CASH FLOW FROM OPERATING ACTIVITIES EBIT -15 979 475 -2 607 665 Government refund (Skattefunn) represents 1,3 MNOK. TAXES PAID 0 0 D

  7. Slide 7: Selected notes cont.

    Selected notes cont. 3. Consolidation 5. MAJOR SHAREHOLDERS NO. OF SHARES % Teigland Eiendom AS 20 691 829 21,1 % Lifecare AS acquired Lifecare NanoBiosensors GmbH in late June Lacal AS 14 187 712 14,5 % Vpf Nordea Avkastning 8 222 700 8,4 % 2021, this is incorporated in the group financial statemen

  8. Slide 8: Outlook – Technology Development

    Outlook – Technology Development Execution of first-in-human clinical pilot study Priority and focus – planning for milestone achievement by end of 1H 2022 Basis for increased R&D activities; clinical and regulatory activities for product development of Sencell Glucose, as well as forming a basis fo

  9. Slide 9: Outlook - Activity and Costs

    Outlook - Activity and Costs Capacity scale-up – headcount and manufacturing Planning to increase staff at headquarters in Bergen and at Lifecare NanoBioSensors with both administrative commercial and scientific personnel, including personnel for production preparations. Currently no plans for addit

  10. Slide 10: Sencell Market Potential

    Sencell Market Potential The basis for the market potential is described in the document “SENCELL Market Assumptions and Commercial Potential, April 2022» available for downloading at www.lifecare.no Direct costs of diabetes for adults reached USD 966 billion worldwide in 2021. The global market for

  11. Slide 11: Global Total Patient Population

    Global Total Patient Population 537M adults living with diabetes (2021), expected to increase to 643m (2030) and 784m (2040). 1/3rd of patients with diabetes need or should take insulin, the potential market for Continous Glucose Monitoring (CGM) reached 179m patients in 2021. 70% of the population

  12. Slide 12: Sencell Potential Target Patient Population

    Sencell Potential Target Patient Population Regions Population Primary Primary Total target targeted by with Target Target population Lifecare diabetes Type 1 Type 2 EU, EEA, UK, 36 Mill 2,3 Mill 6,3 Mill 8,6 Mill CH US, CA 51 Mill 2,7 Mill 7,2 Mill 9,9 Mill High Income 29 Mill 2,1 Mill 5,6 Mill 7,7

  13. Slide 13: Sencell Potential Revenue

    Sencell Potential Revenue Sencell Market share assumptions: Definitions and assumptions: Primary market: Type 1 diabetes patients (T1). Low Case Base Case High Case Secondary market: Type 2 diabetes patients (T2). Primary Market (T1) 3% 5% 10% Secondary Market (T2) 1% 3% 5% Assuming significantly ch

  14. Slide 14: Sencell Target Market – Potential Revenue Calculation

    Sencell Target Market – Potential Revenue Calculation Market penetration Sencell Base Case 2024 2025 2026 2027 2028 2029 2030 Level of assumed market penetration - base case EU, UK, EEA and CH 5% 20 % 40 % 80 % 95 % 100 % 100 % US and CA 0% 0% 10 % 30 % 50 % 75 % 95 % AU, CL, IL, JP, KR, KW, NZ, OM,

  15. Slide 15: Valuedriven Future Milestones

    Valuedriven Future Milestones Lifecare Sencell Conduct Prototype human clinical Conduct Market launch fabrication for trials – pilot human clinical CE mark through clinical trials study trials partnering 1H 2022 1H 2022 2H 2022 1H 2023 2H 2023 LFS-SEN-001 LFS-SEN-002 LFS-SEN-002 LFS-SEN-003 FDA LFS-

  16. Slide 16: Clinical Studies

    Clinical Studies • Wired Needle Sensor LFS-SEN-001 • 15 participants (10 healthy subjects & 5 patients with T1D • 3 days / proof of concept in humans • Implanted Encapsulated Wireless Sensor • 50 patients with type 1 or type 2 diabetes LFS-SEN-002 • 3 months • System performance + biocompatibility •

  17. Slide 17: © LIFECARE

    © LIFECARE

Lifecare — FY2021 Earnings Presentation on 6ix